Rapid Micro Revenue Beats, but Stock Plunges on Widening Losses

Rapid Micro Biosystems reported second-quarter 2026 financial results on August 7, 2026. Total revenue of $8.1 million exceeded analyst expectations by $0.22 million, driven by strong system placements and consumable growth. However, GAAP EPS of -$0.27 missed targets by $0.03. Management reaffirmed full-year guidance, indicating continued strategic execution despite near-term profitability challenges.

Revenue

Total revenue for the second quarter of 2026 increased by 10.9% to $8.1 million, up from $7.3 million in the corresponding period of 2025. This growth was bolstered by a significant milestone: the placement of the 200th Growth Direct system globally, with four additional systems placed during the quarter. Furthermore, consumable revenue surged more than 20% year-over-year, achieving quarterly records in both units and sales value. Recurring revenue also demonstrated robust health, increasing 14% year-over-year to comprise 63% of total revenue.

Earnings/Net Income

Rapid Micro maintained a stable EPS of $-0.27 in Q2 2026, matching the previous year's figure. However, the company’s net loss widened by 9.0% to $-12.92 million, compared to a $-11.86 million loss in Q2 2025. This marks the seventh consecutive year of losses in this fiscal quarter, highlighting persistent financial headwinds. The company reported a record second-quarter total gross margin of 15%, an increase of 11 percentage points year-over-year, reflecting positive progress in margin expansion initiatives.

The EPS performance was mixed, with flat per-share metrics offset by widening net losses and a slight miss against consensus estimates.

Price Action

The stock price of Rapid Micro has tumbled 13.50% during the latest trading day, has plummeted 18.78% during the most recent full trading week, and has edged up 0.58% month-to-date.

Post-Earnings Price Action Review

Rapid Micro’s stock exhibited significant volatility following the earnings release, reflecting investor reaction to the mixed financial results. While revenue growth and margin improvements provided some optimism, the widening net loss and EPS miss weighed on sentiment. The 13.50% single-day decline and 18.78% weekly drop indicate substantial selling pressure, likely driven by concerns over the timeline to profitability despite strong top-line performance. However, the slight month-to-date gain of 0.58% suggests some stabilization or buyer interest at lower levels, as investors weigh the record gross margins and reaffirmed full-year guidance against the ongoing cash burn.

CEO Commentary

Rob Spignesi, President and Chief Executive Officer, reported strong Q2 performance with $8.1 million in revenue, exceeding guidance, and achieving the 200th Growth Direct System placement. He highlighted record consumable revenue and a 15% gross margin, driven by increased system utilization and validation activities. Spignesi emphasized strategic growth through the MilliporeSigma partnership, which is expected to contribute significantly in H2 2026, and noted robust customer interest in full workflow automation and data integrity. He expressed optimism regarding industry tailwinds, including U.S. reshoring and biomanufacturing expansion, which he anticipates will drive growth starting in 2027. Spignesi affirmed that the company’s fundamentals are stronger than ever, with expanding recurring revenue and improving margins providing a solid foundation for continued expansion and long-term shareholder value creation.

Guidance

Rapid Micro reaffirmed its full-year 2026 total revenue guidance of $37 million to $41 million, assuming 30–38 system placements. The company increased its full-year validation guidance to at least 27 systems. For Q3, management expects revenue of at least $9.5 million, including at least seven system placements, with service revenue stepping up sequentially. Gross margin is projected to reach at least 20% in Q3, with Q4 margins expected in the mid to high 20% range. Full-year gross margin is anticipated to be approximately 20%, with product margin in the mid to high single digits and service margin between 45% and 50%. Operating expenses are guided to be between $51 million and $53 million, with non-cash expenses of $8 million. The company expects cash usage to decline meaningfully in H2 2026 as margins expand and revenue increases.

Additional News

Rapid Micro Biosystems announced that Merck MilliporeSigma will host a European Growth Direct Day in October 2026. This event aims to support customer engagement, education, and commercial pipeline development across the European market. The company also reported strong cash positions, with cash, cash equivalents, and short-term investments totaling approximately $20 million as of June 30, 2026. Additionally, the company recently priced a capital raise of $9.8 million, with potential for up to $21.7 million in additional warrant value. These strategic moves underscore Rapid Micro’s focus on expanding its commercial footprint and securing liquidity to support its growth trajectory in the life sciences automation sector.